•   George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    Based upon clinical trial results compared to controls, the U.S. Food and Drug Administration (FDA) has approved additional uses for the drug tucatinib (brand name Tukysa) in combination with trastuzumab and capecitabine.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Research paper from Neurosurgery curated by Editor in Chief George Lundberg, MD, who notes: 

    The best chance a patient has for survival with glioblastoma is the extent to which the tumor is initially removed surgically. The tools discussed in this study can help the surgeon maximize extirpation.

    Go to full paper published in Neurosurgery.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from Good News Network curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved the use of Lynparza (olaparib) for treating  stage 4 pancreatic cancer patients with hereditary BRCA mutation who have not progressed on platinum therapy. A clinical trial showed prolongation of progression free survival in this subset of patients.

    Go to full article published by Good News Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from WebMD curated by Editor in Chief George Lundberg, MD, who notes: 

    An aggressive 3-part approach may offer hope for some patients with stage 4 pancreatic cancer.

    Go to full article published by WebMD.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •  

    Tucatinib and Trastuzumab Deruxtecan Show Promise in HER2+ Breast Cancer

    Smruti Vidwans, PhD

    In 1998, the U.S. Food and Drug Administration (FDA) approved the drug trastuzumab (brand name Herceptin) for people with HER2-positive metastatic breast cancer. Overnight, HER2+ metastatic breast cancer became treatable (though not curable). Subsequent successful clinical studies led to use of trastuzumab earlier in the breast cancer journey—after surgery—to help prevent recurrence, as well as in earlier-stage HER2+ breast cancer. Meanwhile, the FDA approved… Read more »

  •  

    New Treatments For Bladder Cancer in 2020

    Emma Shtivelman, PhD

    In 2019 and early 2020, the U.S. Food and Drug Administration (FDA) approved a number of new drugs for bladder cancer of all stages, and more treatments are on the horizon. Here’s a snapshot of what’s happening right now in bladder cancer treatment: Non-muscle invasive bladder cancer treatments (NMIBC) In patients with NMIBC, tumors are confined to the inner cell layer of the bladder… Read more »

  •  

    Facilitating Access to Treatment for Children with Brain Cancer

    With: Leslie Jared, RN, MSN

    A Q&A with Leslie Jared, RN, MSN, Nurse Navigator at Cancer Commons. Email: leslie.jared@cancercommons.org Q: A midline glioma is a type of brain tumor that is particularly dangerous because of its nature and its location in the brain. It often afflicts children. An investigational drug called ONC201 has shown early promise in some patients whose tumors have a specific genetic mutation called H3 K27M.… Read more »

  •   George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    A treatment that combines two drugs can be beneficial for some patients who have advanced pancreatic cancer with BRCA mutations.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    A large, retrospective study demonstrates that surgical removal of as much tumor tissue as possible results in the best outcomes for patients—seems pretty logical, and is true.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    In precision oncology, drugs combinations may provide new effective treatment.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.